PHILADELPHIA—An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy, according to a new study from researchers at the University of Pennsylvania and Penn's Perelman School of Medicine.
The findings suggest that the Penn-developed tool — which uses artificial intelligence and machine learning to decipher the mixture of volatile organic compounds (VOCs) emitting off cells in blood plasma samples — could serve as a non-invasive approach to screen for harder-to-detect cancers, such as pancreatic and ovarian.
The results will be presented at the annual American Society of Clinical Oncology meeting on June 4 by A. T. Charlie Johnson, PhD, the Rebecca W. Bushnell Professor of Physics and Astronomy in Penn's School of Arts & Sciences (Abstract # 5544).
"It's an early study but the results are very promising," Johnson said. "The data shows we can identify these tumors at both advanced and the earliest stages, which is exciting. If developed appropriately for the clinical setting, this could potentially be a test that's done on a standard blood draw that may be part of your annual physical."
Co-authors include Erica L. Carpenter, PhD, director of the Circulating Tumor Material Laboratory and research assistant professor in the Perelman School of Medicine, Janos Tanyi, MD, PhD, an assistant professor of Obstetrics and Gynecology, and Cynthia Otto, DVM, PhD, director of the Working Dog Center and professor at Penn's School of Veterinary Medicine (Penn Vet). The late George Preti, PhD, of the Monell Chemical Senses Center, is also co-author.
The Penn research team is currently working with VOC Health to commercialize the device, along with others, for research and clinical applications.
The electronic olfaction — "e-nose" — system is equipped with nanosensors calibrated to detect the composition of VOCs, which all cells emanate. Previous studies from the researchers demonstrated that VOCs released from tissue and plasma from ovarian cancer patients are distinct from those released from samples of patients with benign tumors.
Among 93 patients, including 20 patients with ovarian cancer, 20 with benign ovarian tumors and 20 age-matched controls with no cancer, as well as 13 patients with pancreatic cancer, 10 patients with benign pancreatic disease, and 10 controls, the vapor sensors discriminated the VOCs from ovarian cancer with 95 percent accuracy and pancreatic cancer with 90 percent accuracy. The tool also correctly identified all patients (a total of eight) with early-stage cancers.
The technology's pattern recognition approach is similar to the way people's own sense of smell works, where a distinct mixture of compounds tells the brain what it's smelling. The tool was trained and tested to identify the VOC patterns more associated with cancer cells and those associated with cells from healthy blood samples in 20 minutes or less.
The team's collaboration with Richard Postrel, CEO and chief innovation officer of VOC Health, has also led to an improvement in detection speed by 20 fold.
"Collaborating with researchers from the department of Physics and Astronomy, the Perelman School of Medicine, and Penn Vet has allowed us to perfect and integrate our own innovations – expediting the commercialization process," Postrel said. "Initial prototypes of commercial devices able to detect cancer from liquids and vapors will be ready soon and be provided to these Penn researchers to further their work."
In a related effort with VOC Health, Johnson, along with his co-investigator Benjamin Abella, MD, MPhil, a professor of Emergency Medicine, were awarded a two-year, $2 million grant by the National Institutes of Health National Center for Advancing Translational Sciences for the development of a handheld device that can detect the signature "odor" of people with COVID-19, which is based off the cancer-detection technology applied in this study.
Penn co-authors also include Christopher Kehayias, a postdoctoral researcher in Johnson's lab, Jody Piltz-Seymour, MD, a clinical professor in the department of Ophthalmology, Mark O'Hara, MD, an assistant professor of Hematology-Oncology, Taylor A. Black, of the Abramson Cancer Center, and Stephanie S. Yee, lab manager of the CTM Laboratory. Young Eun Lee, PhD, of the Monell Chemical Senses Center, is also a co-author.
Johnson will present the findings during a poster presentation on June 4 at 9 am EST. The research was funded by the Kleberg Foundation.
